Vericel Corporation - Common Stock (VCEL)

Brown Capital Discloses $31 Million Sale of Vericel Stock as Small-Cap Biotech Reports Earnings

Vericel (VCEL) Q3 2025 Earnings Call Transcript

Vericel (VCEL) beats Q3 2025 earnings estimates with strong revenue growth and a swing to profitability, driven by its MACI and burn care products.

Vericel (VCEL) combines strong revenue & earnings growth with a bullish technical setup, making it a top biotech growth stock to watch.

Vericel Corp (VCEL) is a high-growth biotech stock with strong fundamentals and a promising technical setup, making it a potential breakout candidate for investors.

Vericel Corp (VCEL) posted mixed Q2 2025 results with revenue missing estimates but EPS beating expectations. Shares fell 6.5% pre-market despite strong MACI growth and margin expansion.

VERICEL CORP (NASDAQ:VCEL) shows strong growth fundamentals and a technical breakout pattern, making it a stock to watch in the biotech sector.

VERICEL CORP (NASDAQ:VCEL) shows strong revenue and earnings growth, backed by a solid balance sheet and a promising technical breakout pattern.

VERICEL CORP (NASDAQ:VCEL) shows strong growth potential with solid profitability and a promising technical setup, making it a stock worth watching.

The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79.

SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.